Esketamine superior to quetiapine in refractory depression study

Researchers found esketamine nasal spray to be more effective than extended-release quetiapine in adults with treatment-resistant depression taking an SSRI or SNRI.

by Lisa Lytle

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up